Allena Pharmaceuticals Inc (NASDAQ:ALNA)

0.3493
Delayed Data
As of Jan 24
 -0.0357 / -9.27%
Today’s Change
0.32
Today|||52-Week Range
2.78
-41.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$30.9M

Company Description

Allena Pharmaceuticals, Inc. engages in the development, discovery and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

Contact Information

Allena Pharmaceuticals, Inc.
One Newton Executive Park
Newton Massachusetts 02462
P:(617) 467-4577
Investor Relations:

Employees

Shareholders

Mutual fund holders9.87%
Other institutional6.75%
Individual stakeholders14.61%

Top Executives

Louis BrennerPresident, Chief Executive Officer & Director
Geoffrey A. SwireCOO & Senior Vice President-Corporate Development
Richard D. KatzChief Financial & Accounting Officer
David J. ClarkChief Medical Officer
Hugh WightSenior Vice President-Technical Operations